Targeted alpha therapy for metastatic breast cancer using alpha-Herceptin

使用 α-赫赛汀对转移性乳腺癌进行靶向 α 疗法

• 批准号: nhmrc : 222748
• 负责人: Prof Barry Allen
• 金额: $ 22.17万
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Development Grants
• 财政年份: 2003
• 资助国家: 澳大利亚
• 起止时间: 2003-01-01 至 2005-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/targeted-alpha-therapy-alpha-herceptin/97948
• 关键词: Targeted; alpha; therapy; metastatic; breast

The specific aim of this proposal is to demonstrate, in non-human primates, proof–of-concept of a patented new platform vaccine technology (scrambled antigen vaccine or SAVINE) designed to encode all the protein sequences of an infectious agent, in this case HIV-1. These are arranged as equal-sized, overlapping fragments such that all potential T cell epitopes that are needed to induce broad T-cell-mediated immunity are maintained. The synthetically designed vaccine uses consensus sequences of HIV-1 to provide universal coverage of the major HIV-1 strains for a global population. The synthetic systematically designed HIV-1 vaccine will be delivered using our newly developed prime-boost immunisation regime that induces particularly high levels of cell-mediated immunity.

该提案的具体目的是在非人类灵长类动物中证明一种专利的新平台疫苗技术（scrambled antigen vaccine或SAVINE）的概念验证，该技术旨在编码感染因子的所有蛋白质序列，在这种情况下是HIV-1。这些被排列为相等大小的重叠片段，使得诱导广泛T细胞介导的免疫所需的所有潜在T细胞表位得以维持。这种合成设计的疫苗使用HIV-1的共有序列，为全球人口提供主要HIV-1毒株的普遍覆盖。合成的系统设计的HIV-1疫苗将使用我们新开发的引发-加强免疫方案来提供，该方案诱导特别高水平的细胞介导的免疫。